Cytarabine (Mylan Institutional LLC)


Welcome to the PulseAid listing for the Cytarabine drug offered from Mylan Institutional LLC. This Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Mylan Institutional LLC
NON-PROPRIETARY NAME: Cytarabine
SUBSTANCE NAME: CYTARABINE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC]
ROUTE: INTRAVENOUS; SUBCUTANEOUS
DOSAGE FORM: INJECTION
MARKETING CATEGORY NAME: ANDA
START MARKETING DATE: 2011-12-14
END MARKETING DATE: 0000-00-00


Cytarabine HUMAN PRESCRIPTION DRUG Details:

Item DescriptionCytarabine from Mylan Institutional LLC
LABELER NAME: Mylan Institutional LLC
DEA SCHEDULE:
ACTIVE STRENGTH: 20(mg/mL)
START MARKETING DATE: 2011-12-14
END MARKETING DATE: 0000-00-00
PRODUCT ID: 67457-454_a6463842-d20c-4552-adee-c4a1d5de8cbc
PRODUCT NDC: 67457-454
APPLICATION NUMBER: ANDA200914

Other CYTARABINE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Fresenius Kabi USA, LLCCytarabine
Hospira Worldwide, Inc.Cytarabine
Hospira, Inc.CYTARABINE
Mylan Institutional LLCCytarabine
Pfizer Laboratories Div Pfizer Inc.Cytarabine
Sigma-Tau Pharmaceuticals, Inc.DepoCyt